Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $337.7 million, a 20.3% increase from $280.7 million in Q1 2024 [9] - Adjusted earnings per share rose to $1.42, up 17.4% from $1.21 in Q1 2024 [9] - Adjusted EBITDA increased to $40.6 million, a 25.1% rise from $32.4 million in Q1 2024 [9] - Gross margin percentage improved to 31.9% from 31.4% in Q1 2024 [24] - Adjusted EBITDA margin was 12%, compared to 11.6% in Q1 2024 [25] Business Line Data and Key Metrics Changes - Personal Care segment revenues were $258.3 million, accounting for 76.5% of total revenue, with a 7.4% organic revenue growth [23] - Hospice same store revenue increased by 9.9%, with average daily census rising to 3,515, a 4.6% increase year-over-year [14][21] - Home Health segment revenues were $18 million, representing 5.3% of total revenue, with a 1.3% organic revenue growth [22] Market Data and Key Metrics Changes - Personal Care services received favorable reimbursement support, including a 5.5% rate increase in Illinois effective January 1, 2025 [12] - Same store hours in Personal Care increased by 2% compared to Q1 2024, marking the largest year-over-year volume growth in recent quarters [13] - The company experienced solid caregiver hiring success, with 79 hires per day in Personal Care, up from 78 in Q1 2024 [10] Company Strategy and Development Direction - The company aims for a minimum annual revenue growth of 10%, focusing on acquisitions that complement organic growth [17] - The Gentiva acquisition added approximately $280 million in annualized revenues, significantly expanding market coverage [22] - The company is actively pursuing additional acquisition opportunities to enhance density in existing markets and add clinical services [23][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for home-based care, viewing it as a growth opportunity [18] - The company anticipates stable gross margins and consistent cash flow conversion in line with historical averages [25][27] - Management noted that the clinical hiring environment remains challenging, but improvements have been observed in the personal care segment [11][67] Other Important Information - The company utilized approximately $2.5 million in ARPA funding during Q1 2025, with $8.8 million remaining [28] - As of March 31, 2025, the company had cash on hand of approximately $97 million and reduced bank debt by $20 million [9][28] Q&A Session Summary Question: Commentary on hospice cap limitations - Management indicated that cap limitations have not been material, with effective management of referral mix [33][34] Question: Impact of weather on personal care services - Management confirmed weather events affected January but noted a rebound in February and March, expecting hours growth to remain in the 2% to 2.5% range [40][41] Question: Hospice revenue growth expectations - Management projected hospice revenue growth in the 5% to 7% range, leaning towards the upper end [44] Question: Margin expansion expectations - Management expects typical margin expansion of 40 to 50 basis points into Q2, with Q1 usually being the low point [50][51] Question: Impact of Medicaid changes - Management stated that potential changes to Medicaid would likely have no direct impact on the company, as its patient base is primarily elderly and disabled [54][56] Question: Performance of Gentiva post-acquisition - Management reported that Gentiva's bottom line performance has exceeded expectations, while top line growth was slightly lighter than anticipated [77] Question: Update on home health services - Management noted stability in Medicare rates and improvements in contracting with Medicare Advantage plans, with discounts narrowing from 40% to 15-20% [106]

Financial Data and Key Metrics Changes - Consolidated sales for Q1 2025 were $455.2 million, a year-over-year decrease of 1% [14] - Fully diluted earnings per share were $0.67 for Q1 2025, down from $0.70 in Q1 2024 [14] - Gross profit was $163.9 million, slightly up from $163.6 million in the prior year, with a gross margin of 36%, an improvement of 50 basis points [15] - Operating income was $44.1 million, down 8% from $47.9 million in the prior year, with an operating margin of 9.7% [15][16] Business Line Data and Key Metrics Changes - Water Systems segment sales in the U.S. and Canada were up 2%, with groundwater pumping equipment sales increasing by 6% and water treatment products by 7% [17] - Distribution segment sales decreased by 3% to $141.9 million, primarily due to lower volumes and commodity price declines [19] - Energy Systems segment sales increased by 8% to $66.8 million, with operating income rising to $21.9 million and an operating margin of 32.8% [20][21] Market Data and Key Metrics Changes - Water Systems sales outside the U.S. and Canada decreased by 2%, impacted by a 5% decline due to foreign currency translation [18] - The Energy Systems segment recorded growth across key product lines, supported by robust demand in the U.S. energy sector [11] Company Strategy and Development Direction - The company is focused on faster-growing markets, operational efficiency, and integrating recent acquisitions to enhance customer service [6][7] - Strategic acquisitions in Q1 2025 included PumpEng and Barnsley, aimed at expanding product offerings and market reach [28] - The company is committed to innovation and new product development, with a focus on high-growth verticals [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying business fundamentals despite challenges from tariffs and one-time costs [7][10] - The company is adjusting the lower end of its EPS guidance by $0.10, while maintaining full-year sales expectations [24] - Management noted that the business is largely in region for region, which historically tends to be resilient even during economic softness [29] Other Important Information - The effective tax rate for the quarter was 25%, up from 22% in the prior year, impacting EPS by approximately $0.03 [22] - The company ended Q1 2025 with a cash balance of $84 million and used $19.5 million in net cash flows from operating activities [23] Q&A Session Summary Question: Insights on the energy segment margins - Management indicated that while margins are strong, they do not expect the same growth as in previous quarters but anticipate maintaining strong margins due to smarter solutions and effective cost management [34] Question: Order trends in the water segment - Management believes the order growth is organic and not significantly influenced by tariff pull-forward, with selective inventory positioning to mitigate potential tariff impacts [35][36] Question: M&A priorities in the distribution segment - Management remains open to M&A opportunities in the distribution space but is currently focused on operational efficiencies and serving the market [39][40] Question: Tariff exposure and groundwater business performance - Management stated that the overall percentage of COGS from China is under 10%, and groundwater sales in North America showed strong growth, with residential sales up 11% and agricultural sales up 3% [48][51] Question: Organic book to bill ratio in water - The organic book to bill ratio was above one for the quarter, with backlog up mid to high single digits [57]

Financial Data and Key Metrics Changes - In Q1 2025, Integer Holdings Corporation reported sales of $437 million, reflecting a 7% year-over-year increase on a reported basis and a 6% increase on an organic basis [20][13] - Adjusted operating income grew by 14%, with adjusted net income reaching $46 million, up 19% year-over-year, and adjusted earnings per share totaled $1.31, up 15% from the same period last year [22][25] - The company reiterated its sales outlook for 2025, expecting reported growth of 8% to 10% and organic growth of 6% to 8% [14][32] Business Line Data and Key Metrics Changes - Cardiovascular sales increased by 17% in Q1 2025, driven by new product ramps in electrophysiology and contributions from recent acquisitions [22] - Cardiac rhythm management and neuromodulation sales grew by 2% in Q1 2025, with expectations of low to mid-single-digit growth for the full year [23][24] Market Data and Key Metrics Changes - The company expects CNV sales to grow in the mid-teens compared to 2024, while CRM and N sales are projected to grow low to mid-single digits [23][24] - The order book increased to approximately $800 million, reflecting strong demand and new product introductions [82] Company Strategy and Development Direction - Integer Holdings Corporation is focused on building differentiated capabilities and collaborating closely with customers to deliver innovative medical device technologies [12] - The company completed two tuck-in acquisitions, enhancing its service offerings and expanding its capabilities in proprietary coating technologies [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong sales growth, citing high visibility to customer demand and ramping programs in high-growth markets [14][40] - The company is managing its debt leverage within a target range of 2.5% to 3.5% times EBITDA, with a strategic refinancing completed to reduce interest expenses [29][30] Other Important Information - The company raised its adjusted net income outlook by $10 million, reflecting the impact of interest expense savings [34] - Cash flow from operations increased by 35% year-over-year to $31 million, with free cash flow improving by $12 million from the prior year [28][37] Q&A Session Summary Question: Impact of tariffs on adjusted operating income - Management confirmed the estimated impact of tariffs for 2025 remains between $1 to $5 million, with efforts to minimize this impact [44][49] Question: Deceleration in CRM segment growth - Management noted fewer selling days as a headwind and expects mid-single-digit growth in the CRM segment moving forward [50][56] Question: Growth in electrophysiology - Management stated that electrophysiology continues to outgrow the market, contributing significantly to overall cardiovascular growth [60][62] Question: Customer inventory levels and potential impacts - Management indicated no significant changes in customer ordering patterns related to tariffs, viewing any potential changes as timing issues [128][130] Question: Resilience in a recessionary environment - Management expressed confidence in the company's resilience during economic downturns, noting that most therapies supported are not elective [142][145]